A Clinical Study of ICP-488 in Healthy Subjects and Patients With Psoriasis
NCT ID: NCT05451199
Last Updated: 2023-04-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
154 participants
INTERVENTIONAL
2022-07-29
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis
NCT06842199
Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque Psoriasis
NCT06109818
Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis
NCT07251998
Study to Investigate the Safety, Tolerability, Absorption, Distribution, Metabolism, and Elimination of RWJ-445380 Administered to Patients With Plaque Psoriasis
NCT00396422
Multiple-loading Dose Regimen Study in Patients With Chronic Plaque-type Psoriasis
NCT00805480
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ICP-488
Single ascending doses of ICP-488 tablet; Multiple ascending doses of ICP-488 tablet; Part3 Patients with Psoriasis:ICP-488 tablet.
ICP-488
ICP-488 will be administered as tablet
Placebo
Single ascending doses of placebo; Multiple ascending doses of placebo; Part3 Patients with Psoriasis of placebo.
Placebo
Matching placebo will be administered as tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ICP-488
ICP-488 will be administered as tablet
Placebo
Matching placebo will be administered as tablet
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Body mass index (BMI) between 18-26 kg/m2, the weight of male subject should not be less than 50 kg, and the weight of female subject should not be less than 45 kg.
3. The results of laboratory tests during the screening period are within the normal reference values of the population or study site;Or the results were slightly off but within acceptable limits, and the investigator evaluated that they were not clinically significant.
4. Fertility status: Female subjects who are infertile (i.e. physically unable to conceive, including postmenopausal or surgically infertile women);Male subjects and their partners must agree to use effective contraception for the entire study period and for 28 days after the last medication or for five half-lives, and male subjects shall not donate sperm during this period.
5. Male or female subjects aged ≥ 18 years and ≤ 65 years；
6. Diagnosis of plaque psoriasis；
7. All of the following 3 criteria are met at screening and randomization:
1）Psoriasis Area and Severity Index (PASI) ≥ 12; 2）Physician Global Assessment (PGA) ≥ 3; 3）Body surface area (BSA) affected by psoriasis ≥ 10%.
8\. The subject is a candidate to receive systemic therapy and/or phototherapy.
Exclusion Criteria
2. Evidence or history of clinically significant disease, or evidence or history of allergic disease.
3. Subjects with clinically significant gastrointestinal dysfunction that may affect drug intake, transport or absorption.
4. Acute disease state within 14 days before administration.
5. Currently or within 6 months prior to administration experiencing a severe infection or having a long-term or recurrent infection disease
6. Subjects and/or first-degree relatives have a genetic immune deficiency.
7. Major trauma or surgery within 3 months prior to the first administration.
8. Previous medical history of tuberculosis; The presence of investigator-judged signs or symptoms of active tuberculosis and the chest imaging showed active pulmonary tuberculosis at screening ；T-spoT test (T-SPOT) was positive at screening.
9. Urine drug test positive.
10. Alcoholic
11. Subjects who have used tobacco/cigarettes or tobacco/cigarette products within 3 months prior to the first administration.
12. Subjects who donated more than 500 ml of blood (excluding plasma) within 56 days before the first dose, or planned to donate blood or blood components during the study period or within 1 month after the study finished.
13. Use of any other study drug specified in the protocol within 30 days prior to initial administration or within 5 half-lives(refer to whichever is longer).
14. Any traditional Chinese medicine (TCM) and over-the-counter (OTC) drugs, vitamins, systemic steroid hormone therapy, immunosuppressant or modulator therapy, hormone replacement therapy, and other food supplements or herbs were used 30 days before the first dose until follow-up visit.
15. Consume any food or drink containing caffeine within 48 hours prior your first administration.
16. Last use of stron , moderate and weak CYP1A2/CYP3A4 inhibitors or inducers less than 5 half-lives before the first dose of study drug, or planning to take medications, dietary supplements, or foods
17. Diet or dietary treatment within 30 days prior to initial administration or have significant change in eating habits.
18. Eat smoked charcoal fire foods (such as Carbon barbecue,etc) within 1 week prior to the study.
19. Any positive showed in the lab result of syphilis specific antibody, hepatitis C antibody (HCV-Ab), hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb) or human immunodeficiency virus serological antibody (HIV-Ab) during screening.
20. Received vaccination with live virus vaccine, live attenuated vaccine or any live virus component is administered within 6 weeks prior to initial administration, or during the planned study period or within 8 weeks after the end of the study.
21. Non-plaque forms of psoriasis.
22. Drug-induced psoriasis.
23. Are taking or require oral or injectable corticosteroids for any medical condition.
24. Clinically significant test results at the time of screening that, in the investigator's judgment, may cause unacceptable risk to the participant.
25. History of active tuberculosis，active hepatitis B virus、active hepatitis C virus or Syphilis infection.
26. Clinically severe, progressive, or uncontrolled disease at screening； Pregnant female subjects.
27. breastfeeding female subjects.
28. Other situations judged by the investigator to be unsuitable to join this trial.
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing InnoCare Pharma Tech Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Qianjin Lu
Role: PRINCIPAL_INVESTIGATOR
Hospital for Skin Diseases, Chinese Academy of medical Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Second Hospital of Anhui Meidcal University
Hefei, Anhui, China
The First Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Nanyang First People's Hospital
Nanyang, Henan, China
Shiyan Renmin Hospital
Shiyan, Hubei, China
Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of medical Sciences, Peking Union Medical College
Nanjing, Jiangsu, China
Yanbian University Hospital
Yanji, Jilin, China
Hangzhou First People's Hospital
Hangzhou, Zheajing, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Chunjun Yang
Role: primary
Guoqiang Zhang
Role: primary
Rixin Chen
Role: primary
Zudong Meng
Role: primary
Qianjin Lu
Role: primary
Zhehu Jin
Role: primary
Liming Wu
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ICP-CL-01001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.